{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Verona Pharma plc"},"Symbol":{"label":"Symbol","value":"VRNA"},"Address":{"label":"Address","value":"3 MORE LONDON RIVERSIDE, LONDON, SE1 2RE, United Kingdom"},"Phone":{"label":"Phone","value":"+44 2032834200"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma."},"CompanyUrl":{"label":"Company Url","value":"https://www.veronapharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David S. Zaccardelli","title":"President, CEO & Executive Director"},{"name":"Kathleen Rickard","title":"Chief Medical Officer"},{"name":"Kavita Aggarwal","title":"Senior Vice President-Medical Affairs"},{"name":"Tara Rheault","title":"VP-Research & Development, Global Project"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}